The future of pharmaceutical manufacturing in the context of the scientific, social, technological and economic evolution.

Healthcare provision is one of the import elements of modern societies. Life sciences and technology has made substantial progress over the past century and is continuing to evolve exponentially in many different areas. The use of genotypic and phenotypic information in drug discovery and drug therapy, the increasing wealth around the world, growing patient involvement through information and communication technology and finally innovations in pharmaceutical manufacturing technology are transforming the provision of healthcare. The adoption of this new science and technology is going to happen due to the synergistic effects and visible benefits for the society and healthcare systems. The different aspects driving advanced pharmaceutical manufacturing are reviewed to identify future research direction to assure overall acceptance and adoption into healthcare practice.

[1]  C. Ponting,et al.  Finishing the euchromatic sequence of the human genome , 2004 .

[2]  Younghwa Lee,et al.  The Technology Acceptance Model: Past, Present, and Future , 2003, Commun. Assoc. Inf. Syst..

[3]  Kristopher Ray Wilburn.  The business case for continuous manufacturing of pharmaceuticals , 2010 .

[4]  Melissa A. Basford,et al.  Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data , 2013, Nature Biotechnology.

[5]  Kim Hill,et al.  A theory of human life history evolution: Diet, intelligence, and longevity , 2000 .

[6]  J. Kitzmiller,et al.  Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants , 2014, Journal of pharmacogenomics & pharmacoproteomics.

[7]  Deven McGraw,et al.  For telehealth to succeed, privacy and security risks must be identified and addressed. , 2014, Health affairs.

[8]  M. Afilalo,et al.  Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. , 2001, Annals of emergency medicine.

[9]  Urs A Meyer,et al.  Omics and drug response. , 2013, Annual review of pharmacology and toxicology.

[10]  Shu Chuen Li,et al.  Drug-related problems in hospitalized patients on polypharmacy: the influence of age and gender , 2005, Therapeutics and clinical risk management.

[11]  J. Beijnen,et al.  Drug-Drug Interactions in a Geriatric Outpatient Cohort , 2008, Drugs & aging.

[12]  G. K. Raju,et al.  Understanding Pharmaceutical Quality by Design , 2014, The AAPS Journal.

[13]  Janet Morahan-Martin,et al.  How Internet Users Find, Evaluate, and Use Online Health Information: A Cross-Cultural Review , 2004, Cyberpsychology Behav. Soc. Netw..

[14]  H. Kubinyi.  Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.

[15]  J. Brownstein,et al.  Digital disease detection--harnessing the Web for public health surveillance. , 2009, The New England journal of medicine.

[16]  B. Carnes.  How long must humans live , 2015 .

[17]  M. Swan.  Emerging Patient-Driven Health Care Models: An Examination of Health Social Networks, Consumer Personalized Medicine and Quantified Self-Tracking , 2009, International journal of environmental research and public health.

[18]  S. A. Iverson,et al.  Impact of Internet Use on Health-Related Behaviors and the Patient-Physician Relationship: A Survey-Based Study and Review , 2008, The Journal of the American Osteopathic Association.

[19]  R. Elliott,et al.  Problems with Medication Use in the Elderly: An Australian Perspective , 2006 .

[20]  J. Hanlon,et al.  Prevalence of potentially preventable unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events among older veterans. , 2012, The journals of gerontology. Series A, Biological sciences and medical sciences.

[21]  Lawrence X. Yu.  Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control , 2008, Pharmaceutical Research.

[22]  International Human Genome Sequencing Consortium.  Finishing the euchromatic sequence of the human genome , 2004 .

[23]  Charles Auffray,et al.  Predictive, preventive, personalized and participatory medicine: back to the future , 2010, Genome Medicine.

[24]  Erin R Bell.  Melt extrusion and continuous manufacturing of pharmaceutical materials , 2011 .

[25]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[26]  M. Kivimäki,et al.  Comorbidity and Functional Trajectories From Midlife to Old Age: The Health and Retirement Study , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[27]  A. Iorio,et al.  Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. , 2011, European journal of internal medicine.

[28]  J. Balint,et al.  Regaining the initiative. Forging a new model of the patient-physician relationship. , 1996, JAMA.

[29]  A. Avery,et al.  Causes of preventable drug-related hospital admissions: a qualitative study , 2008, Quality & Safety in Health Care.

[30]  C. Eap,et al.  Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance , 2006, Drug safety.

[31]  F. Collins,et al.  First FDA authorization for next-generation sequencer. , 2013, The New England journal of medicine.

[32]  A. Zimmer,et al.  Geriatric drug therapy: Neglecting the inevitable majority , 2010, Ageing Research Reviews.

[33]  Bernhardt L Trout,et al.  Achieving continuous manufacturing for final dosage formation: challenges and how to meet them. May 20-21, 2014 Continuous Manufacturing Symposium. , 2015, Journal of pharmaceutical sciences.

[34]  B. Young,et al.  Social media use among patients and caregivers: a scoping review , 2015 .

[35]  Buket Aksu,et al.  Strategic funding priorities in the pharmaceutical sciences allied to Quality by Design (QbD) and Process Analytical Technology (PAT). , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[36]  Dimitrios I. Gerogiorgis,et al.  Economic Analysis of Integrated Continuous and Batch Pharmaceutical Manufacturing: A Case Study , 2011 .

[37]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[38]  Fred D. Davis,et al.  A Theoretical Extension of the Technology Acceptance Model: Four Longitudinal Field Studies , 2000, Management Science.

[39]  Pablo Villoslada,et al.  Modules, networks and systems medicine for understanding disease and aiding diagnosis , 2014, Genome Medicine.

[40]  Charles Auffray,et al.  Participatory medicine: a driving force for revolutionizing healthcare , 2013, Genome Medicine.

[41]  A. Maslow.  A Theory of Human Motivation , 1943 .

[42]  Avron Spiro,et al.  Personality, health, and aging: prolegomenon for the next generation , 2002 .

[43]  F. Dieterle,et al.  Biomarkers in oncology drug development: rescuers or troublemakers? , 2008, Expert opinion on drug metabolism & toxicology.

[44]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[45]  John W. Meyer,et al.  The Worldwide Expansion of Higher Education in the Twentieth Century , 2005 .

[46]  Ruscin Jm,et al.  Assessment of Medication Management Skills in Older Outpatients , 1996 .

[47]  Bill Saporito.  Survival of the fittest. , 2012, Time.

[48]  Melanie Swan,et al.  Sensor Mania! The Internet of Things, Wearable Computing, Objective Metrics, and the Quantified Self 2.0 , 2012, J. Sens. Actuator Networks.

[49]  T. Semla,et al.  Assessment of Medication Management Skills in Older Outpatients , 1996, The Annals of pharmacotherapy.

[50]  Lyndal Trevena,et al.  Exploring patient involvement in healthcare decision making across different education and functional health literacy groups. , 2009, Social science & medicine.

[51]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2010 , 2010, Nature Biotechnology.

[52]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[53]  Felix W Frueh,et al.  Implementing the U.S. FDA guidance on pharmacogenomic data submissions , 2007, Environmental and molecular mutagenesis.

[54]  Kathryn A. Phillips,et al.  Measuring the value of pharmacogenomics , 2005, Nature Reviews Drug Discovery.

[55]  B. Shastry,et al.  Pharmacogenetics and the concept of individualized medicine , 2006, The Pharmacogenomics Journal.

[56]  F. Collins,et al.  Shattuck lecture--medical and societal consequences of the Human Genome Project. , 1999, The New England journal of medicine.